NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Oasmia Pharmaceutical AB (publ) (ST: OASM)

 
OASM Technical Analysis
5
As on 30th May 2022 OASM STOCK Price closed @ 1.01 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.19 & Strong Sell for SHORT-TERM with Stoploss of 3.86 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

OASMSTOCK Price

Open 1.02 Change Price %
High 1.06 1 Day 0.01 1.00
Low 1.00 1 Week -0.05 -4.72
Close 1.01 1 Month -0.65 -39.16
Volume 741419 1 Year -2.99 -74.75
52 Week High 4.38 | 52 Week Low 1.00
 
ST Sweden Most Active Stocks
QUIA 0.02 0.00%
QLIFE 0.04 0.00%
SBB-B 5.38 3.07%
STRLNG 0.12 33.33%
LUNE 21.97 6.65%
SAS 0.36 5.88%
URBIT 0.02 0.00%
IDOGEN 0.15 -31.82%
STAR-B 0.89 -1.11%
TELIA 24.60 0.41%
 
ST Sweden Top Gainers Stocks
S2M 0.52 100.00%
NETM-B 1.35 42.11%
STRLNG 0.12 33.33%
IVACC 7.26 32.97%
SPRINT 0.63 16.67%
TH1NG 1.61 16.67%
ATIC 5.14 15.77%
ATIC 5.14 15.77%
CIRCHE 3.69 15.67%
AXIC-A 8.16 15.25%
 
ST Sweden Top Losers Stocks
IDOGEN 0.15 -31.82%
IMMU 0.72 -27.27%
ALLR 1.55 -26.54%
MIDW-A 24.80 -22.98%
KILI 0.76 -16.48%
FRACTL 36.80 -14.02%
DIVIO-B 0.13 -13.33%
ZZ-B 41.50 -12.08%
LIPI 1.49 -11.83%
BACTI-B 72.70 -10.69%
 
 
OASM
Daily Charts
OASM
Intraday Charts
Whats New @
Bazaartrend
OASM
Free Analysis
 
OASM Important Levels Intraday
RESISTANCE1.13
RESISTANCE1.09
RESISTANCE1.07
RESISTANCE1.04
SUPPORT0.98
SUPPORT0.95
SUPPORT0.93
SUPPORT0.89
 
OASM Forecast May 2024
4th UP Forecast3.44
3rd UP Forecast2.66
2nd UP Forecast2.18
1st UP Forecast1.7
1st DOWN Forecast0.32
2nd DOWN Forecast-0.16
3rd DOWN Forecast-0.64
4th DOWN Forecast-1.42
 
OASM Weekly Forecast
4th UP Forecast2.63
3rd UP Forecast2.11
2nd UP Forecast1.79
1st UP Forecast1.47
1st DOWN Forecast0.55
2nd DOWN Forecast0.23
3rd DOWN Forecast-0.09
4th DOWN Forecast-0.61
 
OASM Forecast2024
4th UP Forecast8.01
3rd UP Forecast5.76
2nd UP Forecast4.38
1st UP Forecast2.99
1st DOWN Forecast-0.97
2nd DOWN Forecast-2.36
3rd DOWN Forecast-3.74
4th DOWN Forecast-5.99
 
 
OASM Other Details
Segment EQ
Market Capital 1008832448.00
Sector Healthcare
Industry Drug Manufacturers-Specialty & Generic
Offical website >
 
OASM Address
OASM
 
OASM Latest News
 
Your Comments and Response on Oasmia Pharmaceutical AB (publ)
 
OASM Business Profile
Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company offers Apealea/Paclical for the treatment of ovarian cancer. Its products portfolio includes Docetaxel micellar, a patented formulation that combines XR-17 with docetaxel that has completed pre-clinical trial for the treatment of prostate cancer; and Cantrixil, which has completed Phase I clinical trial for the treatment of ovarian cancer. The company also provides combination therapies, such as XR-19 for various forms of cancer, including ovarian, first-line breast, prostate, and lung cancer. In addition, its animal health product portfolio includes Paccal Vet, a patented formulation of paclitaxel for the treatment of mammary carcinoma; and Doxophos Vet, a patented formulation of doxorubicin for the treatment of lymphoma. Oasmia Pharmaceutical AB (publ) was incorporated in 1988 and is headquartered in Uppsala, Sweden. Address: Vallongatan 1, Uppsala, Sweden, 752 28
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service